DUBLIN--(BUSINESS WIRE)--The "Diabetic Macular Edema (DME) - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the DME , historical and forecasted epidemiology as well as the DME market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The DME market report provides current treatment practices, emerging drugs, DME market share of the individual therapies, current and forecasted DME market size from 2018 to 2030 segmented by seven major markets. The Report also covers current DME treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Findings
In 2020, the overall prevalent cases of DME accessed to be around 1,862,529 in the 7MM, which are expected to grow during the forecast period, i.e., 2021-2030.
The disease epidemiology covered in the report provides historical as well as forecasted DME epidemiology [segmented as Total Prevalent Cases of DME, Total Diagnosed Prevalent cases of DME, Gender-specific Diagnosed Prevalent Cases of DME, Age-specific Diagnosed Prevalent Cases of DME, Subgroups-Specific Diagnosed Prevalent Cases of DME and Treated cases of DME] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.
Country Wise- DME Epidemiology
- In the United States, the total number of prevalent cases of DME were 1,026,346 in 2020 which are expected to increase during the forecast period, i.e., 2021-2030.
- In 2020, the total prevalent cases of DME were 641,864 in EU-5, which are projected to increased during the forecast period, i.e., 2021-2030.
- In Japan, the total number of prevalent cases of DME were 194,319 in 2020 which are expected to grow during the forecast period, i.e., 2021-2030.
- Findings from various secondary studies suggest that DME affects more males as compared to females, and is more prevalent in elderly population. In the 7MM, the gender-specific diagnosed cases of DME were 486,120 for males and 352,018 for females, in 2020. In the 7MM, the age-specific diagnosed prevalent cases of DME were 120,436, 363,767 and 353,935 for the age-groups 18-44, 45-64 and ≥75 years, in 2020
- In 2020, 193,979 non-central involved cases of DME and 267,876 central-involved DME cases were observed in the United States
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the DME market.
- To understand the future market competition in the DME market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for DME in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for DME market.
- To understand the future market competition in the DME market.
Companies Mentioned
- Adverum Biotechnologies
- Graybug Vision
- Roche
- Novartis
- KalVista Pharmaceuticals
- Ocuphire Pharma
- Oxurion
- YD Life Science
- Allergan (AbbVie)/Molecular Partners
- Allergo Opthalmics/ Bausch Health
- Kodiak Sciences
- Clearside Biomedical
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s2pcnw
